SUMMARY Shoulder abduction fatiguability has been measured using a hand held myometer in normal subjects and patients with peripheral neuromuscular diseases. An index of fatiguability was based on the decline in force over a series of ten maximum voluntary contractions performed in under a minute. The technique was repeatable and well tolerated. Patients with myasthenia, mitochondrial myopathy and motor neuron disease tended to show excess fatiguability independent of muscle strength. Serial measurements demonstrated alterations in fatiguability but not necessarily strength, associated with changes in symptoms.
Fatiguability is a common symptom in peripheral neuromuscular disease. Commonly the clinician assesses this subjectively by repetitive manual "breaking" of shoulder abduction or some other muscle group. However, this is difficult to quantify and compare from examination to examination. More elaborate techniques utilising electrically stimulated muscle contractions' or isokinetic dynamometry2 have been used, particularly for assessing knee extension, but generally require complex apparatus and are impractical for routine use.
In this study we define fatiguability as the reduction in muscle contraction force with repeated maximum efforts. We have developed a simple technique to quantify fatiguability, which can be employed in the clinic; the percentage decline in shoulder abduction force over ten successive maximum voluntary contractions (MVC), is measured using a hand held dynamometer.
A preliminary report of this work was made at the Association of British Neurologists' Meeting, Belfast, April 1986.
Methods (A) Technique
The subject is seated, the back unsupported, with the nondominant arm to be assessed abducted to 900, the elbow flexed to 900 and the forearm pronated ( fig. 1 ). In the small number of patients where shoulder abduction strength was less than MRC3 grade 3, the fatiguability test was conducted with the patient in supine position. The to + 19-4%, + 2SD): the mean values for males and females were not significantly different (p > 0 1) and the combined values for both sexes was -6-8 to + 19-0% (mean 6 1%). Thus a few subjects showed a slight increase in force (negative values) over 10 contractions. No correlation was found between Fl and strength (p = >0-1).
As mentioned in Methods, the effect of deviations from the starting position was examined. There was found to be no significant difference (p = 0.4) 
Shoulder abduction fatiguability between MVCs at 900 and 60°of abduction, or MVCs at 900 and 600 of forward flexion in abduction. Therefore it seems unlikely that any failure to maintain the starting position would account for an increase in fatiguability index. Inter-observer variation was low; the correlation coefficient between Fl measured by two examiners in 11 patients was 0-96 (p < 0.01). Patients classified as fatiguable all had a Fatigue Index (FI) > 20%; those whose initial strength (mean of first two contractions) was more than 2SD below the normal mean for sex were considered weak. In many of those with myasthenia, fatiguability was very abnormal; one third had an FT of more than 50%. Of the fatiguable myasthenic group, 70% were weak, but in 30% strength fell within the normal range. There was no statistically significant correlation between weakness and fatiguability in patients with myasthenia gravis or congenita. In the group with Lambert Eaton Syndrome there was a tendency for the Fl to increase (that is, more fatiguable) with increasing strength but this did not reach conventional statistical significance (r = 0-52, p = 0-08, n = 11). Within the mitochondrial myopathy group, 40% had a significant FT (ie > 20%); however, the mean for the whole group was 18 3%, considerably higher than the combined mean for normal males and females (mean = 6-1%). The four patients with neuropathy who showed excess fatiguability, all had Guillain-Barre syndrome, but none Case History 1. (fig 3) A female patient, aged 61 years with neurosarcoidosis and proximal weakness, was treated with prednisolone. Shoulder abduction strength, and that of other muscle groups recorded, only improved slightly. However, the FI declined markedly (that is, reduced fatiguability), in parallel with a striking improvement in her general symptoms. was admitted for a course of plasma exchange. In the following three weeks, muscle strength changed minimally but her fatiguability index improved as did her timed walking and symptomatic state.
Case History 3. (fig 5) A male, age 25 years with Guillain-Barre syndrome, was followed up over four months. In contrast to the other two cases, muscle strength improved greatly but the FI still remained high. Late improvement in fatiguability may account for the prolonged period required to return to premorbid fitness.
Discussion
The term "muscle fatigue" has been used to refer to a variety of phenomena associated with prolonged or repeated contractions. These include a decline in force,6 selective force loss at high7 or low frequencies8 of electrical stimulation, slowing of contractile properties9 and changes in the EMG power spectrum'0 and muscle fibre conduction velocity." By using the term fatiguability, we refer to the clinically apparent reduction in maximum voluntary strength with repeated contractions. The technique described has allowed us to express also weak as were two of the non-fatiguable patients. None of the undiagnosed group with non-specific "weakness and fatigue" were shown to have significant fatiguability (mean FI 7-6%, range 1 to 14 4%, n = 5) despite 60% being weak.
Although it might be expected that pathophysiological processes leading to fatiguability and weakness would be similar, we find that in our population of patients there is no simple correlation. This is confirmed in the limited serial data on treated patients which demonstrates that strength and fatiguability in individual muscle groups may vary independently. We are now collecting more serial data on patients with a view to investigating this more closely.
Few tests of fatiguability applicable to patients have been described in the literature. Test of timed performance'3 in which the time that the head or leg can be held in a standard position have been used, but seem to be more dependent on the patient's motivation and, in our hands produce rather variable results. In one study14 these tests were found to discriminate between diseased and normal muscle, but were an insensitive means of monitoring progress.
Many authors have previously emphasised the value of serial strength measurements in monitoring patients with peripheral neuromuscular diseases;4 nevertheless, we are aware that a few patients complain more of fatiguability than weakness. The fatiguability index can be used to document excessive fatiguability in shoulder abduction but it should not be assumed that FT will be similar in other muscle groups. Serial measurements may indicate changes in clinical state which are not obvious from examination in simple strength measurements, but which the patient finds significant. The test appears robust, easy to perform and reliable, but as with all such tests, should be interpreted in conjunction with changes in symptoms, clinical performance and strength.
